|Day Low/High||36.10 / 37.29|
|52 Wk Low/High||14.56 / 52.95|
Investors in PTC Therapeutics Inc saw new options begin trading today, for the August 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 10th contracts and identified one put and one call contract of particular interest.
Investors in PTC Therapeutics Inc saw new options become available today, for the August 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new August 3rd contracts and identified one put and one call contract of particular interest.
Sarepta adds another 7% on top of nearly 40% gains on Tuesday following good results for a new gene therapy.
But rival firm PTC Therapeutics tumbles nearly 31% on the news.
The Dow and S&P 500 declined Monday as investors react to last week's escalation in the ongoing trade war between Washington and Beijing.
Updated interim data from a study of risdiplam were presented June 16 at the 22nd Annual SMA Researcher Meeting.
- risdiplam (RG7916) is well tolerated at all dose levels with no drug-related safety findings -
SOUTH PLAINFIELD, N.J.
- European Commission ratification anticipated in coming months -
Investors in PTC Therapeutics Inc saw new options become available today, for the July 13th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PTCT options chain for the new July 13th contracts and identified one put and one call contract of particular interest.
On April 17, 2018, PTC Therapeutics, Inc. (NASDAQGS:PTCT) ("PTC" or the "Company"), in its capacity as a nominal defendant, entered into a Stipulation of Settlement (the "Stipulation") in the above-captioned shareholder derivative action -- in which three...
- First patient dosed in Type 1 Spinal Muscular Atrophy Program -
- Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30, 2018
Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in PTC Therapeutics Inc , where a total of 3,147 contracts have traded so far, representing approximately 314,700 underlying shares. That amounts to about 46.8% of PTCT's average daily trading volume over the past month of 672,560 shares.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in PTC Therapeutics Inc , where a total volume of 6,631 contracts has been traded thus far today, a contract volume which is representative of approximately 663,100 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 75.2% of PTCT's average daily trading volume over the past month, of 882,305 shares.
The most recent short interest data has been released for the 10/13/2017 settlement date, which shows a 1,353,958 share increase in total short interest for PTC Therapeutics Inc , to 8,436,994, an increase of 19.12% since 09/29/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Former Attorney General of Louisiana, Charles C. Foti, Jr.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.